Despite FDA support, master protocols have been slow to take hold in the U.S. due to reluctance and lack of coordination among the trial industry to take on such large-scale studies. But researchers who have been busy setting up and running master protocols during the pandemic say the challenges in the U.S. are surmountable with advance planning that includes streamlined contracting, expedited IRB approval and site staff training.